GlassScriptPhysician profile
Timothy D Williams
NPI 1174939789
$10,540.10
in general payments reported to CMS, 2019-2025
46 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,812 · 2020: $388 · 2021: $1,799 · 2022: $2,227 · 2023: $1,582 · 2024: $1,591 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,808.08 | 2019-2025 | |
| Abbvie INC. | $1,144.37 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $924.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $920.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $865.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $584.26 | 2019-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.87 | 2019-2024 | Jardiance, Ofev |
| Abbott Laboratories | $416.28 | 2021-2025 | Freestyle Libre 3, Eterna |
| E.R. Squibb & Sons, L.L.C. | $330.46 | 2020-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $317.01 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.36 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $277.61 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $250.17 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $219.42 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $199.51 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.